Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Team Grant: E-Rare Joint Transnational Call

University of Toronto

$299,136.00

Unveiling the role of glutamate in dopamine transporter deficiency syndrome

EF 2019-20

Résumé
Dopamine transmission in the brain is a tightly regulated process, and alterations in dopamine signaling result in several disease with enormous human and economic burden, including schizophrenia, ADHD, Bipolar disorder, Parkinson's disease and dyskinesias. One of the key regulators of dopamine transmission is the plasma membrane dopamine transporter, DAT, which transports released dopamine back into the neuron. In addition to the above prevalent diseases, there is also a rare, fatal disease caused by mutations in the dopamine transporter, called dopamine transporter deficiency syndrome. We have developed several models to study dopamine transporter deficiency syndrome and in this study we will be assessing the effects of various drug treatments on these models to see if they can have beneficial effects. We hypothesize that manipulating neurotransmitters in the brain could improve some of the sympotms associated with dopamine transporter deficiency syndrome. Positive results from our studies could be quickly translated into the clinic, since the drugs that we will be testing are already an approved and used in humans.
Programme
Team Grant: E-Rare Joint Transnational Call
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406765
Name
Salahpour Ali
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Fund for Scientific Research (FRS); Ministry of Education, Universities and Research (Rome); The Netherlands Organization for Health Research and Development (ZonMw); Research Council of Lithuania (RCL)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Unveiling the role of glutamate in dopamine transporter deficiency syndrome
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$299,136
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Dopamine Transporter Deficiency Syndrome; Dopamine Transporter Knockout Mutation; Dopamine;; Glutamate;; Infantile Dystonia-Parkinsonism; Ipsc Cells.; Pharmacology,
Abstract
Dopamine transmission in the brain is a tightly regulated process, and alterations in dopamine signaling result in several disease with enormous human and economic burden, including schizophrenia, ADHD, Bipolar disorder, Parkinson's disease and dyskinesias. One of the key regulators of dopamine transmission is the plasma membrane dopamine transporter, DAT, which transports released dopamine back into the neuron. In addition to the above prevalent diseases, there is also a rare, fatal disease caused by mutations in the dopamine transporter, called dopamine transporter deficiency syndrome. We have developed several models to study dopamine transporter deficiency syndrome and in this study we will be assessing the effects of various drug treatments on these models to see if they can have beneficial effects. We hypothesize that manipulating neurotransmitters in the brain could improve some of the sympotms associated with dopamine transporter deficiency syndrome. Positive results from our studies could be quickly translated into the clinic, since the drugs that we will be testing are already an approved and used in humans.
Competitiondate
201906
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Salahpour, Ali
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $299,136~ $0~